Show simple item record

Rapid Re-expansion of a Macroprolactinoma After Early Discontinuation of Bromocriptine

dc.contributor.authorOrrego, John J.en_US
dc.contributor.authorChandler, William F.en_US
dc.contributor.authorBarkan, Ariel L.en_US
dc.date.accessioned2006-09-11T19:02:31Z
dc.date.available2006-09-11T19:02:31Z
dc.date.issued2000-11en_US
dc.identifier.citationOrrego, John J.; Chandler, William F.; Barkan, Ariel L.; (2000). "Rapid Re-expansion of a Macroprolactinoma After Early Discontinuation of Bromocriptine." Pituitary 3(3): 189-192. <http://hdl.handle.net/2027.42/47493>en_US
dc.identifier.issn1386-341Xen_US
dc.identifier.issn1573-7403en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/47493
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=11383485&dopt=citationen_US
dc.description.abstractProlactin (PRL)-secreting pituitary adenomas are the most common functioning pituitary tumors. Medical treatment with dopamine agonists is the therapy of choice for macroprolactinomas (≥10 mm). Withdrawal of bromocriptine after weeks or months of uninterrupted therapy has been associated with rapid tumor re-expansion as evidenced by x-ray and CT scanning of the pituitary region. We report a patient with a giant macroprolactinoma who had a dramatic response to bromocriptine (tumor volume shrinkage of 53% within a month) but rapid re-expansion to its original dimensions one week after discontinuation of bromocriptine. To our knowledge, this is the first time that the rapid shrinkage/re-expansion of a macroprolactinoma has been documented with serial MRI scans.en_US
dc.format.extent91462 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherKluwer Academic Publishers; Springer Science+Business Mediaen_US
dc.subject.otherMedicine & Public Healthen_US
dc.subject.otherDiabetesen_US
dc.subject.otherNeurosurgeryen_US
dc.subject.otherHyperprolactinemiaen_US
dc.subject.otherProlactinomaen_US
dc.subject.otherBromocriptineen_US
dc.subject.otherPituitary Tumorsen_US
dc.subject.otherDopamine Agonistsen_US
dc.titleRapid Re-expansion of a Macroprolactinoma After Early Discontinuation of Bromocriptineen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelPublic Healthen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumSection of Neurosurgery, Department of Surgery, Pituitary and Neuroendocrine Center, USA; Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michiganen_US
dc.contributor.affiliationumSection of Neurosurgery, Department of Surgery, Pituitary and Neuroendocrine Center, USA; Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michiganen_US
dc.contributor.affiliationumSection of Neurosurgery, Department of Surgery, Pituitary and Neuroendocrine Center, USA; Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michiganen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid11383485en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/47493/1/11102_2004_Article_324060.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1023/A:1011412028660en_US
dc.identifier.sourcePituitaryen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.